Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  sorafenib tosylate
Find trials that include:  Any drugs shown
Results 1-25 of 55 for your search:
Start Over
Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer and Hepatitis C Infection
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-213, NCI-2013-01103, NCT01849588
Sorafenib Long Term Extension Program (STEP)
Phase: Phase III
Type: Treatment
Age: 16 and over
Trial IDs: 12311, NCI-2012-01207, 2007-002604-17, NCT00625378
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-103, NCI-2012-01029, NCT01556490
Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 1112, NCI-2012-02057, NCT01730937
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-104, NCI-2013-00676, 2012-005375-14, NCT01887717
Sorafenib Tosylate in Treating Patients with Desmoid Tumors or Aggressive Fibromatosis
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091105, NCI-2014-00264, PA091105_A04PAMDREVW01, NCT02066181
TRC105 and Sorafenib Tosylate in Treating Patients with Liver Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0102, NCI-2013-01477, 110102, 339029, P10766, NCT01306058
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BTTC09-01, NCI-2011-03056, NCT01434602
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients with Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1153, NCI-2012-00095, CDR0000720022, NCCTG-N1153, NCT01497444
Sorafenib, Vorinostat, and Bortezomib in Treating Patients With Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IUCRO-0327, NCI-2012-00200, NCT01534260
Ascorbic Acid and Sorafenib Tosylate in Treating Patients with Metastatic Liver Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 12D.424, NCI-2014-01892, 2012-40, NCT01754987
Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A041-05, NCI-2014-01930, ACE-041, NCT02024087
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBIHCC-103, NCI-2014-02447, NCT02279719
Sorafenib Tosylate, Cisplatin, and Paclitaxel before Surgery in Treating Patients with Stage I-IIIA Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: WCI1590-08, NCI-2011-03389, NCT01194869
Erlotinib Hydrochloride, Akt Inhibitor MK2206, Selumetinib, or Sorafenib Tosylate in Treating Patients with Previously Treated Stage III-IV Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-0360, NCI-2011-01104, NCT01248247
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: 7195, NCI-2012-01084, CA180-392, NCT01620216
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11-003311, NCI-2012-00911, NCT01624285
Trebananib with or without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients with Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHII-122, NCI-2012-01289, CDR0000738785, P9048_A12PAMDREVW01, 9048, NCT01664182
Temsirolimus and Sorafenib Tosylate in Treating Patients With Stage II-IV Liver Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 85
Trial IDs: 124511, NCI-2012-02021, NCT01687673
Sorafenib Tosylate and Combination Chemotherapy in Treating Patients with Advanced Liver Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-218, NCI-2013-00627, NCT01775501
Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients with Recurrent or Progressive High-Grade Glioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-14816, NCI-2013-00705, CTC-11-011, NCT01817751
Sorafenib Tosylate and Doxorubicin Hydrochloride in Treating Patients with Advanced Liver Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-259, NCI-2013-00867, NCT01840592
Chemotherapy, Surgery, and Radiation Therapy in Treating Patients with Newly Diagnosed, Localized Rhabdomyosarcoma
Phase: Phase II
Type: Treatment
Age: Under 22
Trial IDs: RMS13, NCI-2013-00913, NCT01871766
Start Over